134 related articles for article (PubMed ID: 16585569)
1. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
Schumacher LY; Vo DD; Garban HJ; Comin-Anduix B; Owens SK; Dissette VB; Glaspy JA; McBride WH; Bonavida B; Economou JS; Ribas A
J Immunol; 2006 Apr; 176(8):4757-65. PubMed ID: 16585569
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Hallett WH; Ames E; Motarjemi M; Barao I; Shanker A; Tamang DL; Sayers TJ; Hudig D; Murphy WJ
J Immunol; 2008 Jan; 180(1):163-70. PubMed ID: 18097016
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
4. Immunosensitization with a Bcl-2 small molecule inhibitor.
Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
[TBL] [Abstract][Full Text] [Related]
6. Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells.
Lundqvist A; Su S; Rao S; Childs R
J Immunol; 2010 Feb; 184(3):1139-42. PubMed ID: 20026740
[TBL] [Abstract][Full Text] [Related]
7. Sensitizing tumor cells to immune-mediated cytotoxicity.
Shanker A; Sayers T
Adv Exp Med Biol; 2007; 601():163-71. PubMed ID: 17713003
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
Straube C; Wehner R; Wendisch M; Bornhäuser M; Bachmann M; Rieber EP; Schmitz M
Leukemia; 2007 Jul; 21(7):1464-71. PubMed ID: 17495970
[TBL] [Abstract][Full Text] [Related]
9. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Amiri KI; Horton LW; LaFleur BJ; Sosman JA; Richmond A
Cancer Res; 2004 Jul; 64(14):4912-8. PubMed ID: 15256463
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Ames E; Hallett WH; Murphy WJ
Clin Exp Immunol; 2009 Mar; 155(3):504-13. PubMed ID: 19220837
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
Basler M; Lauer C; Beck U; Groettrup M
J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
[TBL] [Abstract][Full Text] [Related]
14. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
15. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
Hu W; Zheng RR; Cui HX; Yue D; Wang Y; Jiang YH
Asian J Androl; 2012 Sep; 14(5):695-702. PubMed ID: 22902909
[TBL] [Abstract][Full Text] [Related]
16. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
18. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
20. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
